Ipsen S.A. publishes its 2023 Consolidated Financial Statements
- 15 February 2024 - 1 mins read
Ipsen S.A. – 2023 Consolidated Financial Statements
Attachment
24 April 2024
7 mins read
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
22 April 2024
5 mins read
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
02 April 2024
7 mins read
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
13 February 2024
14 mins read
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
08 February 2024
8 mins read
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
22 January 2024
10 mins read
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
07 December 2023
10 mins read
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
07 December 2023
5 mins read
Capital Markets Day 2023 – Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
26 October 2023
7 mins read
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
23 October 2023
8 mins read